

Immediate Release

19 January 2006

**ANGEL BIOTECHNOLOGY HOLDINGS PLC**  
**(“Angel” or “the Company”)**

**Angel announces GMP manufacturing contract for autologous cell therapy**

**Angel Biotechnology Holdings plc**, (AIM: ABH) the biopharmaceutical contract manufacturer, that was recently admitted to AIM, is pleased to announce a GMP Manufacturing deal with a US-based company.

Under the contract, valued at US \$0.8 million, Angel will manufacture and supply GMP materials for use in an autologous cell therapy in UK-based clinical trials. The cells will be used in a novel area of transplant medicine and this is Angel’s first contract to provide a GMP mammalian cell product for use in clinical trials. The work, to be conducted at Angel’s facilities in Cramlington and Edinburgh, will commence later this month for a duration of 9 months.

Commenting on the contract, Gordon Sherriff, Angel’s Chief Operating Officer said “This is a significant project for Angel. We are delighted to have been selected by the company to be its manufacturing partner. The nature of the work is highly specialist and draws on Angel’s core expertise in finding GMP solutions for such projects. The project fits well with Angel’s strategic direction and will significantly enhance our reputation in the field. Almost 60% of our 2006 target has now been reached with a further 11.5 months of our financial year remaining and a substantial pipeline of high value prospects to pursue.”

**For further information, please call:**

**Angel Biotechnology Holdings plc**

Gordon Sherriff – COO

Dr Paul Harper – Executive Chairman

**Buchanan Communications**

Lisa Baderoon/Mary-Jane Johnson

Tel 01670 591920

Tel 07951 057016

Tel 07747 842446

Tel 020 7466 5000

**About Angel Biotechnology Holdings plc**

Angel Biotechnology Holdings plc is a fast growing biomanufacturing company offering process development services and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.

Angel is managed by a team that has more than 100 years' combined experience in pharmaceutical and biopharmaceutical manufacture, gained in companies such as Glaxo, SmithKline Beecham and Serologicals Inc.

Angel operates out of two sites, at Cramlington near Newcastle upon Tyne and at Pentlands Science Park, near Edinburgh.

Angel was established in 2000 and listed on AIM in November 2005.